Avicena Group to Present at 2006 BIO InvestorForum

PALO ALTO, CA., October 13, 2006 — Avicena Group, Inc. (OTCBB: AVGO), a biotechnology company focused on the commercialization of its proprietary cellular energy modulation platform technology, announced today that Avicena's Chief Executive Officer Belinda Tsao-Nivaggioli, Ph.D., will deliver a corporate presentation at the 2006 Biotechnology Industry Organization InvestorForum. The conference, which is by invitation only, will be held from October 17 - 19, 2006 at The Palace Hotel in San Francisco.

Dr. Tsao-Nivaggioli's presentation will take place at 9:30 a.m. PT on Thursday, October 19. The presentation will provide an overview of the Company's drug development pipeline as well as its dermaceutical products. A live webcast and 30-day archive of the presentation can be accessed at www.avicenagroup.com.

ABOUT THE AVICENA GROUP
Based in Palo Alto, CA, Avicena is a biotechnology company that seeks to develop and commercialize therapeutic products that regulate the critical energy processes which occur within human cells. Avicena's focus is on the development of pharmaceutical products to treat patients with rare diseases (orphan drugs), as well as dermaceutical and nutraceutical products. To date, the company has advanced certain compounds for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) into Phase III trials. Near term, the company intends to initiate a Phase III trial in Huntington's disease as well as Parkinson's disease.

SAFE HARBOR
This release may contain forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements reflect, among other things, management's current expectations, plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict. See "Risk Factors" in the company's prospectus and annual report for a discussion of such risks, including the company's need for additional funds, the company's dependence on a limited number of therapeutic compounds, the early state of the products the company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the company's ability to avoid infringement of the patent rights of others, and the company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. Avicena does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.